Determinants of coronary collateral circulation in patients with coronary artery disease;Koroner arter hastaliǧi olan hastalarda koroner kollateral gelişiminin belirteçleri

Anadolu Kardiyoloji Dergisi

Volumn 13, Issue 2, 2013, Pages 146-151

  Zorkun, Cafer ^a   Akkaya, Emre ^a   Zorlu, Ali ^b   Tandoǧan, Izzet ^b  

^a Clinic of Cardiology Yedikule Thoracic Diseases and Surgery Education and Research Hospital ^*  (Turkey)

^b CUMHURIYET UNIVERSITY   (Turkey)

Author keywords

Coronary artery disease; Coronary collateral circulation; High sensitivity c reactive protein; Regression analysis

Indexed keywords

ANTITHROMBOCYTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; C REACTIVE PROTEIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FIBRINOGEN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIPID; NITRATE; PROTEIN C; PROTEIN S; URIC ACID;

ANGIOCARDIOGRAPHY; ARTICLE; CARDIOVASCULAR PARAMETERS; COHORT ANALYSIS; CORONARY ARTERY COLLATERAL CIRCULATION; CORONARY ARTERY DISEASE; CORONARY ARTERY OBSTRUCTION; DIABETES MELLITUS; DISEASE ASSOCIATION; DISEASE SEVERITY; FEMALE; GENSINI SCORE; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; OUTCOME ASSESSMENT; PROTEIN BLOOD LEVEL; RETROSPECTIVE STUDY; SEX DIFFERENCE; BLOOD; COLLATERAL CIRCULATION; METABOLISM; MIDDLE AGED; PATHOPHYSIOLOGY; REGRESSION ANALYSIS; RISK FACTOR; SEVERITY OF ILLNESS INDEX;

C-REACTIVE PROTEIN; COHORT STUDIES; COLLATERAL CIRCULATION; CORONARY ARTERY DISEASE; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MIDDLE AGED; REGRESSION ANALYSIS; RETROSPECTIVE STUDIES; RISK FACTORS; SEVERITY OF ILLNESS INDEX;

EID: 84878392794     PISSN: None     EISSN: 13080032     Source Type: Journal    
DOI: 10.5152/akd.2012.250     Document Type: Article

References (35)

1. Fujita M, Sasayama S, Ohno A, Nakajima H, Asanoi H. Importance of angina for development of collateral circulation. Br Heart J 1987; 57: 139-43.[CrossRef]
2. Elayda MA, Mathur VS, Hall RJ, Massumi GA, Garcia E, de Castro CM. Collateral circulation in coronary artery disease. Am J Cardiol 1985; 55: 58-60.[CrossRef]
3. Seiler C. The human coronary collateral circulation. Heart 2003; 89: 1352-7.[CrossRef]
4. Williams DO, Amsterdam EA, Miller RR, Mason DT. Functional significance of coronary collateral vessels in patients with acute myocardial infarction: relation to pump performance, cardiogenic shock and survival. Am J Cardiol 1976; 37: 345-51.[CrossRef]
5. Ramanathan KB, Wilson JL, Ingram LA, Mirvis DM. Effects of immature recruitable collaterals on myocardial blood flow and infarct size after acute coronary occlusion. J Lab Clin Med 1995; 125: 66-71
6. Habib GB, Heibig J, Forman SA, Brown BG, Roberts R, Terrin ML, et al. Influence of coronary collateral vessels on myocardial infarct size in humans. Results of phase I thrombolysis in myocardial infarction (TIMI) trial. Circulation 1991; 83: 739-46.[CrossRef]
7. Pohl T, Seiler C, Billinger M, Herren E, Wustmann K, Mehta H, et al. Frequency distribution of collateral flow and factors influencing collateral channel development. Functional collateral channel measurement in 450 patients with coronary artery disease. J Am Coll Cardiol 2001; 38: 1872-8.[CrossRef]
8. Abaci A, Oǧuzhan A, Kahraman S, Eryol NK, Unal S, Arinc H, et al. Effect of diabetes mellitus on formation of coronary collateral vessels. Circulation 1999; 99: 2239-42.[CrossRef]
9. Kurotobi T, Sato H, Kinjo K, Nakatani D, Mizuno H, Shimizu M, et al. Reduced collateral circulation to the infarct-related artery in elderly patients with acute myocardial infarction. J Am Coll Cardiol 2004; 44: 28-34.[CrossRef]
10. Waltenberger J. Impaired collateral vessel development in diabetes: potential cellular mechanisms and therapeutic implications. Cardiovasc Res 2001; 49: 554-60.[CrossRef]
11. Alberti KG, Eckel RH, Grundy SM, Zimmet PZ, Cleeman JI, Donato KA, et al. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation 2009; 120: 1640-5.[CrossRef]
12. Gensini GG. A more meaningful scoring system for determining the severity of coronary heart disease. Am J Cardiol 1983; 51: 606.[CrossRef]
13. Schultz A, Lavie L, Hochberg I, Beyar R, Stone T, Skorecki K, et al. Interindividual heterogeneity in the hypoxic regulation of VEGF: significance for the development of the coronary artery collateral circulation. Circulation 1999; 100: 547-52.[CrossRef]
14. Ege MR, Acikgoz S, Zorlu A, Sincer I, Guray Y, Guray U, et al. Mean platelet volume: An important predictor of coronary collateral development. Platelets 2012 May 30. [Epub ahead of print] [CrossRef]
15. Meier P, Hemingway H, Lansky AJ, Knapp G, Pitt B, Seiler C. The impact of the coronary collateral circulation on mortality: a metaanalysis. Eur Heart J 2012; 33: 614-21. [CrossRef]
16. Meier P, Indermuehle A, Pitt B, Traupe T, de Marchi SF, Crake T, et al. Coronary collaterals and risk for restenosis after percutaneous coronary interventions: a meta-analysis. BMC Med 2012; 10: 62.
17. Ross R. Atherosclerosis an inflammatory disease. N Engl J Med 1999; 340: 115-26. [CrossRef]
18. Ridker PM, Cushman M, Stampfer MJ, Tracy RP, Hennekens CH. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med 1997; 336: 973-9. [CrossRef]
19. Ridker PM, Buring JE, Shih J, Matias M, Hennekens CH. Prospective study of C-reactive protein and the risk of future cardiovascular events among apparently healthy women. Circulation 1998; 98: 731-3. [CrossRef]
20. Koenig W, Sund M, Frohlich M, Fischer HG, Lowel H, Doring A, et al. C-reactive protein, a sensitive marker of inflammation, predicts future risk of coronary heart disease in initially healthy middleaged men: results from the MONICA (Monitoring Trends and Determinants in Cardiovascular Disease) Augsburg Cohort Study, 1984 to 1992. Circulation 1999; 99: 237-42. [CrossRef]
21. Gulec S, Ozdemir AO, Maradit-Kremers H, Dincer I, Atmaca Y, Erol C. Elevated levels of C-reactive protein are associated with impaired coronary collateral development. Eur J Clin Invest 2006; 36: 369-75. [CrossRef]
22. Frohlich M, Imhof A, Berg G, Hutchinson WL, Pepys MB, Boeing H, et al. Association between C-reactive protein and features of the metabolic syndrome: a population-based study. Diabetes Care 2000; 23: 1835-9. [CrossRef]
23. den Engelsen C, Koekkoek PS, Gorter KJ, van den Donk M, Salome PL, Rutten GE. High-sensitivity C-reactive protein to detect metabolic syndrome in a centrally obese population: a crosssectional analysis. Cardiovasc Diabetol 2012; 11: 25. [CrossRef]
24. Kinlay S, Timms T, Clark M, Karam C, Bilodeau T, Ridker PM, et al. Comparison of effect of intensive lipid lowering with atorvastatin to less intensive lowering with lovastatin on C-reactive protein in patients with stable angina pectoris and inducible myocardial ischemia. Am J Cardiol 2002; 89: 1205-7. [CrossRef]
25. Ridker PM, Rifai N, Clearfield M, Downs JR, Weis SE, Miles JS, et al. Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events. N Engl J Med 2001; 344: 1959-65. [CrossRef]
26. Ridker PM, Rifai N, Pfeffer MA, Sacks FM, Moye LA, Goldman S, et al. Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events (CARE) Investigators. Circulation 1998; 98: 839-44. [CrossRef]
27. Dincer İ, Ongun A, Turhan S, Ozdol C, Ertaş F, Erol C. Effect of statin treatment on coronary collateral development in patients with diabetes mellitus. Am J Cardiol 2006; 97:7 72-4.
28. Nishikawa H, Miura S, Zhang B, Shimomura H, Arai H, Tsuchiya Y, et al. Pravastatin promotes coronary collateral circulation in patients with coronary artery disease. Coron Artery Dis 2002; 13: 377-81. [CrossRef]
29. Piek JJ, Koolen JJ, Hoedemaker G, David GK, Visser CA, Dunning AJ. Severity of single-vessel coronary arterial stenosis and duration of angina as determinants of recruitable collateral vessels during balloon angioplasty occlusion. Am J Cardiol 1991;67:13-7. [CrossRef]
30. Zbinden R, Zbinden S, Billinger M, Windecker S, Meier B, Seiler C. Influence of diabetes mellitus on coronary collateral flow: an answer to an old controversy. Heart 2005; 91: 1289-93. [CrossRef]
31. Olijhoek JK, Koerselman J, de Jaegere PP, Verhaar MC, Grobbee DE, van der Graaf Y, et al. Presence of the metabolic syndrome does not impair coronary collateral vessel formation in patients with documented coronary artery disease. Diabetes Care 2005; 28: 683-9. [CrossRef]
32. Mouquet F, Cuilleret F, Susen S, Sautiere K, Marboeuf P, Ennezat PV, et al. Metabolic syndrome and collateral vessel formation in patients with documented occluded coronary arteries: association with hyperglycaemia, insulin-resistance, adiponectin and plasminogen activator inhibitor-1. Eur Heart J 2009; 30: 840-9. [CrossRef]
33. Imaizumi S, Miura S, Nishikawa H, Iwata A, Zhang B, Kawamura A, et al. Angiotensin II type 1 receptor blockers do not promote coronary collateral circulation in patients with coronary artery disease. Hypertens Res 2006; 29: 135-41. [CrossRef]
34. Billinger M, Raeber L, Seiler C, Windecker S, Meier B, Hess OM. Coronary collateral perfusion in patients with coronary artery disease: effect of metoprolol. Eur Heart J 2004; 25: 565-70. [CrossRef]
35. Cohen MV, Downey JM, Sonnenblick EH, Kirk ES. The effects of nitroglycerin on coronary collaterals and myocardial contractility. J Clin Invest. 1973; 52: 2836-47. [CrossRef]